Levi & Korsinsky, LLP announces that a ODT class action lawsuit has been filed on behalf of investors who purchased Odonate Therapeutics, Inc. (ODT) securities between December 7, 2017 and April 21, 2020. For more on the ODT Lawsuit please contact us today.
According to the lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company’s orally administered chemotherapy agent, tesetaxel, was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel’s commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in you have until November 16, 2020 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.